NTBU.org
MEET w/Dr Gemi
QuantumGenic™ | Bioenhancement Reimagined
AI-Optimized CNS Delivery + Superfood-Based Human Performance Platform. Revolutionary technology targeting the $50B brain bioavailability market with a dual-track revenue model and global licensing potential.
A $50B Bottleneck in Brain Bioavailability
The pharmaceutical industry faces a critical challenge: delivering therapeutic compounds effectively to the central nervous system (CNS). Despite billions in R&D investment, the blood-brain barrier remains a formidable obstacle that prevents approximately 98% of potential CNS therapeutics from reaching their targets.
Meanwhile, consumers increasingly seek cognitive enhancement solutions, but the current market is flooded with unvalidated products lacking scientific rigor or regulatory approval. This creates a significant market opportunity for science-backed innovations that can overcome these barriers.
CNS Delivery Challenge
Blood-brain barrier blocks most therapeutic compounds, creating a $50B bottleneck in effective drug delivery
Extended Development Cycles
Traditional R&D requires 10-15 years and $1B+ per approved CNS compound
Market Demand
Consumers seek scientifically validated brain enhancement while pharma needs next-gen delivery technology
Our Revolutionary Dual Solution
QuantumGenic (QG)
AI-optimized blood-brain barrier penetration technology using proprietary NanoCarrier Matrix and Lipid Transduction Agent to dramatically improve CNS compound delivery.
Super Soldier Serum (SSS)
Modular biotech platform for human performance enhancement utilizing LiptoCore Biotic Complex and Microbiotic Release Core for optimized bioavailability.
Our PHARMA.AI partnership powers our compound discovery and delivery system, creating a regulatory-aligned pathway through FDA and EU/UK frameworks with robust intellectual property protection.
Multi-Billion Dollar Market Opportunity
QuantumGenic is strategically positioned at the intersection of two massive growth markets: the $2.8 trillion global wellness industry and the $50+ billion CNS drug development sector. The nutraceutical component alone is expanding at an impressive 17.9% CAGR, creating multiple avenues for sustainable growth.
Our targeted market penetration strategy aims for 0.05% in Year 1, scaling to 0.2% by Year 5. This conservative approach still yields significant revenue potential through our dual-track model.
Two Tracks. One Scalable Business Model.
Track A: Pharma Licensing
  • $10M-$50M per licensing agreement
  • 5-10% royalty structure on net sales
  • 5-20 partner targets over 5-year horizon
  • Lower operational complexity
Track B: Direct-to-Consumer
  • Super Soldier Serum retail channel
  • 70-85% gross margins
  • E-commerce and wellness partnerships
  • Brand building opportunity

Financial Trajectory: EBITDA positive by Year 2 | Cash flow positive by Year 3
This dual-track approach creates multiple revenue streams while mitigating risk. The D2C channel provides immediate market feedback and revenue, while pharma licensing offers exponential long-term upside with minimal operational overhead.
Unmatched Competitive Advantage
QuantumGenic has secured a first-mover advantage in AI-validated bioenhancement technology. Our partnership with PHARMA.AI—currently utilized by 10 of the top 20 pharmaceutical companies—provides unparalleled computational capabilities for compound discovery and optimization.
Our proprietary intellectual property portfolio creates significant barriers to entry, while our established regulatory roadmap accelerates time-to-market. This comprehensive approach delivers 40-60% cost savings compared to traditional R&D methodologies.
40-60%
R&D Cost Reduction
10
Top Pharma AI Partners
4
Proprietary IP Components
Substantial Traction & Strategic Partnerships
1
Government Contracts
  • GSA Contract #47QREA23D002D
  • WOSB Certification #200521
  • Federal procurement pathway established
2
Commercial Progress
  • 3 AI-discovered assets already licensed to pharma
  • B2B relationships across healthcare verticals
  • $500K allocated for clinical validation
3
Regulatory Strategy
  • Clinical trials (RCT + observational) planned
  • Global regulatory preparation underway
  • Compliance framework developed with partners
These established relationships and contractual frameworks provide QuantumGenic with a solid foundation for accelerated growth. Our traction demonstrates market validation while reducing execution risk for investors.
Strategic Roadmap to Market Dominance
1
60 Days
Close $1.5M seed round and initiate AI platform integration
2
90 Days
Begin product development and clinical trial preparation
3
6 Months
Complete regulatory dossier and tech build
4
12 Months
Launch D2C channel and initiate licensing discussions
5
5-7 Years
Exit: Strategic buyout (3-5x) or IPO
Our execution strategy prioritizes rapid market entry through the D2C channel while simultaneously building value through clinical validation and IP development. This parallel approach maximizes investor returns while minimizing time-to-revenue.
Smart Capital Allocation for Maximum ROI
Clinical Trials
$500K (33.3%)
AI Platform
$100K (6.7%)
Regulatory
$175K (11.7%)
Tech & Manufacturing
$256K (17.1%)
Marketing
$160K (10.7%)
Operations/Contingency
$309K (20.6%)
Exceptional Margin Profile
Our business model delivers industry-leading gross margins:
70-85%
Direct Sales Margin
Premium positioning and efficient manufacturing yield exceptional D2C margins
95%+
Licensing Margin
B2B licensing agreements generate near-pure profit with minimal overhead
This capital-efficient model enables us to reach profitability with minimal additional investment beyond the seed round, creating a clear path to self-sustainability.
World-Class Leadership
Dr. Gemi Bertran, PhD, MBA
Founder & CEO, Nourish the Brain Institute
PhD in NeuroScience with specialty focus on the Impact of Superfoods on Neurotransmitter Regulation and Neural Pathways for Brain Recovery
Medical Director for Veteran Advocacy Council (VAC)
MBA in Biotechnology Innovation with emphasis on commercialization strategies
Published researcher with expertise in brain optimization and suicide prevention
GSA & WOSB certified entrepreneur with regulatory compliance expertise
Strategic Investment Opportunity: $1.5M Seed Round
We're seeking $1.5 million in strategic investment to accelerate our go-to-market strategy across both business tracks. This capital will fund our clinical validation studies, regulatory preparation, AI platform integration, manufacturing setup, and initial marketing efforts.
This seed round represents an opportunity to secure an early position in a company targeting massive markets with a science-backed, AI-powered solution. Our capital efficiency and dual revenue streams create multiple paths to significant returns.
Investor Benefits
  • Equity stake in holding company with significant upside
  • Revenue participation in lucrative licensing deals
  • Multiple exit options: Buyout / IPO / Acquisition
  • Rights of first refusal on future funding rounds
  • Exposure to both wellness and pharmaceutical sectors
Join the Future of Brain Bioenhancement
QuantumGenic represents a unique opportunity to transform CNS drug delivery and human performance enhancement through AI-optimized technology. Our dual-track business model creates immediate revenue potential while building long-term pharmaceutical licensing value.
By addressing the critical blood-brain barrier challenge, we're unlocking billions in potential value across multiple markets. Our science-backed approach, regulatory roadmap, and experienced leadership team position us for rapid growth and sustainable competitive advantage.

Ready to Transform Brain Bioenhancement?
Schedule a detailed discussion with Dr. Gemi to explore investment opportunities and partnership potential.
Contact: Drgemi@ntbu.org
Scientific Foundation & Clinical Validation
Our proprietary technologies are built on established scientific principles with proven clinical potential. The QuantumGenic platform leverages advanced nanotechnology to overcome blood-brain barrier limitations through innovative mechanisms:
  • NanoCarrier Matrix enhances compound stability and targeted delivery
  • LiptoCore Biotic Complex optimizes bioavailability and absorption
  • Lipid Transduction Agent facilitates improved BBB penetration
  • Micro-biotic Release Core ensures controlled compound release
  • Our planned clinical validation studies will demonstrate efficacy through rigorous randomized controlled trials and observational studies, creating a robust scientific foundation for both regulatory approval and marketing claims.
Global Market Expansion Strategy
Phase 1: North American Launch
Initial focus on U.S. and Canadian markets through direct-to-consumer channels and preliminary pharmaceutical partnership discussions.
  • E-commerce platform development
  • Key opinion leader engagement
  • Preliminary FDA discussions
Phase 2: European Expansion
Strategic entry into EU/UK markets leveraging established regulatory frameworks and wellness-focused consumer base.
  • EU regulatory approval pathway
  • Distribution partnerships
  • Localized marketing campaigns
Phase 3: Global Licensing
Worldwide pharmaceutical licensing strategy targeting leading CNS-focused companies in major markets.
  • Asian market entry
  • Global IP protection strategy
  • Multinational clinical partnerships
This phased approach allows for strategic resource allocation while progressively building global market presence and pharmaceutical industry credibility. Our intellectual property strategy includes comprehensive international protections to secure long-term licensing value.